Article

Australia's TGA approves suspension for subfoveal CNV from wet AMD

Australia's Therapeutic Goods Administration (TGA) approved Alcon's 15-mg anecortave acetate suspension (Retaane) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). The drug should be used where there is a classic component.

As part of a clinical trial agreement, the company will provide the suspension to the U.S. National Eye Institute for a study of wet AMD.

The multicenter, randomized, prospective clinical trial will investigate the long-term safety and efficacy of 15-mg anecortave acetate suspension in patients with all forms of wet AMD and who are undergoing intravitreal bevacizumab (Avastin, Genentech) therapy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.